These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 33413096

  • 21. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).
    Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, Kuder J, Murphy SA, Jukema JW, Lewis BS, Tokgozoglu L, Somaratne R, Sever PS, Pedersen TR, Sabatine MS.
    Circulation; 2018 Jan 23; 137(4):338-350. PubMed ID: 29133605
    [Abstract] [Full Text] [Related]

  • 22. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K, Sharma M, Ferdinand KC.
    Nutr Metab Cardiovasc Dis; 2016 Oct 23; 26(10):853-62. PubMed ID: 27352986
    [Abstract] [Full Text] [Related]

  • 23. Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients With Acute Coronary Syndrome　- The ODYSSEY J-IVUS Trial.
    Ako J, Hibi K, Tsujita K, Hiro T, Morino Y, Kozuma K, Shinke T, Otake H, Uno K, Louie MJ, Takagi Y, Miyauchi K.
    Circ J; 2019 Sep 25; 83(10):2025-2033. PubMed ID: 31434809
    [Abstract] [Full Text] [Related]

  • 24. Inflammatory and Cholesterol Risk in the FOURIER Trial.
    Bohula EA, Giugliano RP, Leiter LA, Verma S, Park JG, Sever PS, Lira Pineda A, Honarpour N, Wang H, Murphy SA, Keech A, Pedersen TR, Sabatine MS.
    Circulation; 2018 Jul 10; 138(2):131-140. PubMed ID: 29530884
    [Abstract] [Full Text] [Related]

  • 25. Alirocumab as add-on therapy to statins: current evidence and clinical potential.
    Auer J, Berent R.
    Ther Adv Cardiovasc Dis; 2018 Jul 10; 12(7):191-202. PubMed ID: 29792380
    [Abstract] [Full Text] [Related]

  • 26. The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Sterol Absorption Markers in a Cohort of Real-World Patients.
    Brandt EJ, Benes LB, Lee L, Dayspring TD, Sorrentino M, Davidson M.
    J Cardiovasc Pharmacol Ther; 2019 Jan 10; 24(1):54-61. PubMed ID: 29940784
    [Abstract] [Full Text] [Related]

  • 27. PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network.
    Chamberlain AM, Gong Y, Shaw KM, Bian J, Song WL, Linton MF, Fonseca V, Price-Haywood E, Guhl E, King JB, Shah RU, Puro J, Shenkman E, Pawloski PA, Margolis KL, Hernandez AF, Cooper-DeHoff RM.
    J Am Heart Assoc; 2019 May 07; 8(9):e011246. PubMed ID: 31020929
    [Abstract] [Full Text] [Related]

  • 28. Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol.
    Colhoun HM, Leiter LA, Müller-Wieland D, Cariou B, Ray KK, Tinahones FJ, Domenger C, Letierce A, Israel M, Samuel R, Del Prato S.
    Cardiovasc Diabetol; 2020 Feb 08; 19(1):14. PubMed ID: 32035487
    [Abstract] [Full Text] [Related]

  • 29. Comparative effects of high-dose atorvastatin versus rosuvastatin on lipid parameters, oxidized low-density lipoprotein, and proprotein convertase subtilisin kexin 9 in acute coronary syndrome.
    Altunkeser BB, Tuncez A, Ozturk B, Tezcan H, Ates MS, Yilmaz C, Yalcin MU, Aygul N, Demir K.
    Coron Artery Dis; 2019 Jun 08; 30(4):285-290. PubMed ID: 30741744
    [Abstract] [Full Text] [Related]

  • 30. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects.
    Wan H, Gumbiner B, Joh T, Riel T, Udata C, Forgues P, Garzone PD.
    Clin Ther; 2017 Nov 08; 39(11):2243-2259.e5. PubMed ID: 29037448
    [Abstract] [Full Text] [Related]

  • 31. PCSK9 inhibitors: clinical evidence and implementation.
    Sabatine MS.
    Nat Rev Cardiol; 2019 Mar 08; 16(3):155-165. PubMed ID: 30420622
    [Abstract] [Full Text] [Related]

  • 32. PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety.
    Roth EM, Davidson MH.
    Rev Cardiovasc Med; 2018 Mar 08; 19(S1):S31-S46. PubMed ID: 30207556
    [Abstract] [Full Text] [Related]

  • 33. PCSK9 Inhibitors in Secondary Prevention-An Opportunity for Personalized Therapy.
    Board C, Kelly MS, Shapiro MD, Dixon DL.
    J Cardiovasc Pharmacol; 2020 May 08; 75(5):410-420. PubMed ID: 32379108
    [Abstract] [Full Text] [Related]

  • 34. Low Density Lipoprotein (LDL) Cholesterol as a Causal Role for Atherosclerotic Disease: Potential Role of PCSK9 Inhibitors.
    Del Pinto R, Grassi D, Properzi G, Desideri G, Ferri C.
    High Blood Press Cardiovasc Prev; 2019 Jun 08; 26(3):199-207. PubMed ID: 31236902
    [Abstract] [Full Text] [Related]

  • 35. Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment Implications.
    Wasserman SM, Sabatine MS, Koren MJ, Giugliano RP, Legg JC, Emery MG, Doshi S, Liu T, Somaratne R, Gibbs JP.
    J Cardiovasc Pharmacol Ther; 2018 Sep 08; 23(5):423-432. PubMed ID: 29768954
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. What Proportion of Patients Admitted with Stroke or Transient Ischemic Attack May Be Suitable for Newer Cholesterol-Lowering Treatment?
    Alakbarzade V, Pereira AC.
    J Stroke Cerebrovasc Dis; 2020 Jan 08; 29(1):104457. PubMed ID: 31732461
    [Abstract] [Full Text] [Related]

  • 38. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A, Watts GF.
    Clin Ther; 2013 Aug 08; 35(8):1082-98. PubMed ID: 23932550
    [Abstract] [Full Text] [Related]

  • 39. Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.
    Ray KK, Vallejo-Vaz AJ, Ginsberg HN, Davidson MH, Louie MJ, Bujas-Bobanovic M, Minini P, Eckel RH, Cannon CP.
    Atherosclerosis; 2019 Sep 08; 288():194-202. PubMed ID: 31253441
    [Abstract] [Full Text] [Related]

  • 40. Effect of Evolocumab on Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies.
    Toth PP, Jones SR, Monsalvo ML, Elliott-Davey M, López JAG, Banach M.
    J Am Heart Assoc; 2020 Mar 03; 9(5):e014129. PubMed ID: 32114889
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.